Cargando…

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results

BACKGROUND: Lenacapavir (LEN) is a highly potent, long-acting, first-in-class inhibitor of HIV-1 capsid protein for the treatment of HIV-1 infection in adults with multidrug resistance (MDR) in combination with other antiretrovirals. METHODS: CAPELLA is an ongoing, phase 2/3 study in heavily treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogbuagu, Onyema, DeJesus, Edwin, Berhe, Mezgebe, Richmond, Gary J, Ruane, Peter J, Sinclair, Gary I, Ramgopal, Moti N, Sanchez, William, Crofoot, Gordon E, Margot, Nicolas A, Wang, Hui, Dvory-Sobol, Hadas, Rhee, Martin, Baeten, Jared, Segal-Maurer, Sorana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677747/ http://dx.doi.org/10.1093/ofid/ofad500.1431

Ejemplares similares

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results
por: Ogbuagu, Onyema, et al.
Publicado: (2022)

848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial
por: Cespedes, Michelle, et al.
Publicado: (2021)

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks
por: VanderVeen, Laurie, et al.
Publicado: (2021)

1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80
por: Kumar, Princy N, et al.
Publicado: (2023)

Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2022)

Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)

IEEE P1596 (SCI) Working Group Meeting
Publicado: (1991)

The Future of HCV Therapy: NS4B as an Antiviral Target
por: Dvory-Sobol, Hadas, et al.
Publicado: (2010)

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations
por: Cilento, Maria E., et al.
Publicado: (2022)

Michelangelo Merisi da Caravaggio (1571–1610). Basket of Fruit (1596)
por: Potter, Polyxeni
Publicado: (2003)

P1596: PREDIAGNOSTIC ANTIMICROBIAL USE IN CLL, MM, FL AND DLBCL
por: Packness, E. M., et al.
Publicado: (2022)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

1251. 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials
por: Ramgopal, Moti, et al.
Publicado: (2022)

Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir
por: Bester, Stephanie M., et al.
Publicado: (2022)

Curbing Ebola infections among healthcare workers in West Africa: unconventional strategies needed
por: Ogbuagu, Onyema Eberechukwu, et al.
Publicado: (2014)

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV
por: Swanstrom, Adrienne E., et al.
Publicado: (2023)

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
por: Cespedes, Michelle, et al.
Publicado: (2022)

1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine
por: Brar, Indira, et al.
Publicado: (2020)

1596P SERONCOVID: Seroconversion in solid-tumor cancer patients (p) after COVID-19 diagnosis
por: Pous, A., et al.
Publicado: (2021)

Extensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and Strategies
por: Ogbuagu, Onyema, et al.
Publicado: (2014)

Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen Class
por: Jacobson, Karen, et al.
Publicado: (2017)

Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting: A retrospective cohort study
por: Jacobson, Karen, et al.
Publicado: (2018)

661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
por: Emu, Brinda, et al.
Publicado: (2019)

GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors
por: Selyutina, Anastasia, et al.
Publicado: (2021)

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model
por: Bekerman, Elena, et al.
Publicado: (2023)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)
por: Dillon, Ryan J, et al.
Publicado: (2020)

887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial
por: Huhn, Gregory D, et al.
Publicado: (2019)

HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir
por: Troyano-Hernáez, Paloma, et al.
Publicado: (2022)

1596 Spectrum of Kaposi's sarcoma encountered among HIV-infected patients in an inner-city hospital in the established antiretroviral era
por: Nguyen, Minh Ly, et al.
Publicado: (2014)

1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Alosaimy, Sara, et al.
Publicado: (2019)

Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda
por: Kambutse, Immaculate, et al.
Publicado: (2018)

Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin
por: Carr, Amy, et al.
Publicado: (2017)

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
por: Ackerman, Peter, et al.
Publicado: (2021)

647. Diagnoses Associated with Temperature ≥104°F in Adults
por: Chi, Sharon, et al.
Publicado: (2019)

1596. Thinking Locally: Can Unit-Specific Methicillin-Resistant Staphylococcus aureus Screening Augment Stewardship Interventions for Febrile Neutropenia?
por: Bartash, Rachel, et al.
Publicado: (2018)

A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding?
por: Tuan, Jessica, et al.
Publicado: (2021)

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study
por: Huhn, Gregory D, et al.
Publicado: (2019)

599. Expanding HIV Training in Internal Medicine Residency Program: A Prospect to Meet the HIV Workforce Demand
por: Barakat, Lydia, et al.
Publicado: (2018)

Correction: Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda
por: Kambutse, Immaculate, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_36fh8300niul2sjvh3unfk0jvq